Search

Displaying results 2641 - 2650 of 10000 in total
  1. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the

    Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE
  2. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929] … [L63798] Thyroid eye disease has historically been managed differently depending on whether it is caught in the active inflammatory phase or has become chronic - Viridian describes veligrotug-vvze as the

  3. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor.

  4. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes … As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis.

  5. Drug

    Influenza A virus A/Michigan/45/2015 X-275 (H1N1) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14422
    ApprovedInvestigational

    Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Mixtures: Efluelda Tetra Injektionssuspension in einer FertigspritzeSynonyms: Influenza A virus A/Michigan/45/2015 X-275 (H1N1) hemagglutinin antigen (formaldehyde inactivated)
  6. Drug

    rsPSMA Vaccine

    go.drugbank.com/drugs/DB06361
    ApprovedWithdrawn

    rsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.

  7. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    [A232384] _Ginkgo biloba_ was investigated in preliminary studies for a variety of therapeutic purposes such as improving cardiovascular health, sexual dysfunction, psychiatric disorders, skin disorders … [A232389] After its nootropic properties were discovered, _ginkgo biloba_ has gained attention as a therapeutic ingredient for memory and concentration enhancement in cognitive impairment and neurogenerative

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: GINKGO AL 40 MG FTA, GINKGO AL 80 MG FTA
  8. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients

  9. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. … It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.

  10. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605] … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.